Intraperitoneal administration (i.p.)of BCT (1 mg/kg or 2 mg/kg, once every three days) significantly inhibited the growth of subcutaneously implanted 22RV1 xenograft tumor (Figure 3B-C). The gene discussed is PCYT1B; the disease is neoplasm.